These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 11958901)

  • 1. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer.
    Firat S; Bousamra M; Gore E; Byhardt RW
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):1047-57. PubMed ID: 11958901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group.
    Firat S; Byhardt RW; Gore E
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):357-64. PubMed ID: 12243808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
    Rades D; Setter C; Dahl O; Schild SE; Noack F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):442-7. PubMed ID: 20950963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival.
    Werner-Wasik M; Scott C; Cox JD; Sause WT; Byhardt RW; Asbell S; Russell A; Komaki R; Lee JS
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1475-82. PubMed ID: 11121651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?
    Ma JT; Sun L; Sun X; Xiong ZC; Liu Y; Zhang SL; Huang LT; Han CB
    Radiat Oncol; 2017 Feb; 12(1):34. PubMed ID: 28143532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
    Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
    Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery.
    Taylor NA; Liao ZX; Stevens C; Walsh G; Roth J; Putnam J; Fossella F; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):616-25. PubMed ID: 12788166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
    Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
    Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
    Werner-Wasik M; Scott C; Graham ML; Smith C; Byhardt RW; Roach M; Andras EJ
    Int J Radiat Oncol Biol Phys; 1999 May; 44(2):327-31. PubMed ID: 10760427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to treatment in patients with stage III non-small cell lung cancer.
    Wang L; Correa CR; Hayman JA; Zhao L; Cease K; Brenner D; Arenberg D; Curtis J; Kalemkerian GP; Kong FM
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):790-5. PubMed ID: 19231108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of gross tumor volume for definitive radiation therapy in patients with locoregionally recurrent non-small-cell lung cancer after surgical resection.
    Lee NK; Moon SH; Kim TH; Han JY; Yun T; Kim HT; Lee HS; Kim MS; Lee JM; Cho KH; Lee JS
    Clin Lung Cancer; 2013 Jul; 14(4):399-406. PubMed ID: 23276823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number.
    Wang S; Ma Z; Yang X; Wang Y; Xu Y; Xia W; Chen R; Qiu M; Jiang F; Yin R; Xu L; Xu K
    Radiat Oncol; 2017 Dec; 12(1):207. PubMed ID: 29284511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of early mortality following stereotactic body radiotherapy for peripheral early-stage lung cancer.
    Baker S; Sharma A; Peric R; Heemsbergen WD; Nuyttens JJ
    Acta Oncol; 2019 Feb; 58(2):237-242. PubMed ID: 30451552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC).
    Firat S; Pleister A; Byhardt RW; Gore E
    Am J Clin Oncol; 2006 Jun; 29(3):252-7. PubMed ID: 16755178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC).
    Rades D; Setter C; Dunst J; Dahl O; Schild SE; Noack F
    Strahlenther Onkol; 2010 Jun; 186(6):307-14. PubMed ID: 20437013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of non-small cell lung cancer histology on survival as measured by the graded prognostic assessment in patients with brain metastases treated by hypofractionated stereotactic radiotherapy.
    Ma LH; Li G; Zhang HW; Wang ZY; Dang J; Zhang S; Yao L
    Radiat Oncol; 2016 Jul; 11():92. PubMed ID: 27411944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.
    Sibley GS; Jamieson TA; Marks LB; Anscher MS; Prosnitz LR
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):149-54. PubMed ID: 9422571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which is the Role of Pneumonectomy in the Era of Parenchymal-Sparing Procedures? Early/Long-Term Survival and Functional Results of a Single-Center Experience.
    Janet-Vendroux A; Loi M; Bobbio A; Lococo F; Lupo A; Ledinot P; Magdeleinat P; Roche N; Damotte D; Regnard JF; Alifano M
    Lung; 2015 Dec; 193(6):965-73. PubMed ID: 26411589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary resection in patients aged 80 years or over with clinical stage I non-small cell lung cancer: prognostic factors for overall survival and risk factors for postoperative complications.
    Okami J; Higashiyama M; Asamura H; Goya T; Koshiishi Y; Sohara Y; Eguchi K; Mori M; Nakanishi Y; Tsuchiya R; Miyaoka E;
    J Thorac Oncol; 2009 Oct; 4(10):1247-53. PubMed ID: 19609223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.